S'abonner

National Trends in Active Surveillance for Prostate Cancer: Validation of Medicare Claims-based Algorithms - 17/09/18

Doi : 10.1016/j.urology.2018.06.037 
Parth K. Modi a, , Samuel R. Kaufman a , Ji Qi a , Brian R. Lane b , Michael L. Cher c , David C. Miller a , Brent K. Hollenbeck a , Vahakn B. Shahinian d , James M. Dupree a
a Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI 
b Urologic Oncology, Spectrum Health, Grand Rapids, MI 
c Department of Urology, Wayne State University, Detroit, MI 
d Division of Nephrology, Department of Medicine, University of Michigan, Ann Arbor, MI 

Address correspondence to: Parth K. Modi, M.D., Dow Division of Health Services Research, Department of Urology, University of Michigan, NCRC, Building 16, 117-W, 2800 Plymouth Rd., Ann Arbor, MI 48109-2800.Dow Division of Health Services ResearchDepartment of UrologyUniversity of MichiganNCRC, Building 16, 117-W, 2800 Plymouth Rd.Ann ArborMI
Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Monday 17 September 2018

Résumé

Objective

To better describe the real-world use of active surveillance. Active surveillance is a preferred management option for low-risk prostate cancer, yet its use outside of high-volume institutions is poorly understood. We created multiple claims-based algorithms, validated them using a robust clinical registry, and applied them to Medicare claims to describe national utilization.

Materials and Methods

We identified men with prostate cancer from 2012-2014 in a 100% sample of Michigan Medicare data and linked them with the Michigan Urologic Surgery Improvement Collaborative (MUSIC) registry. Using MUSIC treatment assignment as the standard, we determined the performance of 8 claims-based algorithms to identify men on active surveillance. We selected 3 algorithms (the most sensitive, the most specific, and a balanced algorithm incorporating age and comorbidity) and applied them to a 20% national Medicare sample to describe national trends.

Results

We identified 1186 men with incident prostate cancer and completely linked data. Eight algorithms were tested with sensitivity ranging from 23.5% to 88.2% and specificity ranging from 93.5% to 99.1%. We found that the use of surveillance for men with incident prostate cancer increased from 2007 to 2014, nationally. However, among all men in the population, there was a large decrease in the rate of prostate cancer diagnosis and an increased or stable rate in the use of active surveillance, depending on the algorithm used. Less than 25% of men on active surveillance underwent a confirmatory prostate biopsy.

Conclusion

We describe the performance of claims-based algorithms to identify active surveillance.

Le texte complet de cet article est disponible en PDF.

Plan


 Funding Disclosure: Funding for the Michigan Urological Surgery Improvement Collaborative (MUSIC) and the Michigan Value Collaborative (MVC) is provided by Blue Cross Blue Shield of Michigan (BCBSM) as part of the Blue Cross Blue Shield of Michigan Value Partnerships program; however, the opinions, beliefs and viewpoints expressed by the authors do not necessarily reflect those of Blue Cross Blue Shield of Michigan or any of its employees. Additional support from NCI T32CA180984 (PM), AHRQ R01HS257007 (BH), NCI R01CA168691 (VS). JMD receives salary support from Blue Cross Blue Shield of Michigan (BCBSM) for his roles in the Michigan Urological Surgery Improvement Collaborative and Michigan Value Collaborative. The views expressed in this article do not reflect the views of the federal government.


© 2018  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.